Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR) Short Interest Update

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCRGet Rating) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 7,900 shares, a decrease of 18.6% from the April 15th total of 9,700 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 10,600 shares, the short-interest ratio is presently 0.7 days.

Several hedge funds and other institutional investors have recently made changes to their positions in EUCR. Deerfield Management Company L.P. Series C bought a new position in shares of Eucrates Biomedical Acquisition during the fourth quarter worth approximately $9,760,000. Goldman Sachs Group Inc. increased its stake in shares of Eucrates Biomedical Acquisition by 1,476.7% during the first quarter. Goldman Sachs Group Inc. now owns 553,622 shares of the company’s stock worth $5,448,000 after purchasing an additional 518,510 shares during the period. D. E. Shaw & Co. Inc. increased its stake in shares of Eucrates Biomedical Acquisition by 172.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 478,669 shares of the company’s stock worth $4,672,000 after purchasing an additional 302,988 shares during the period. Eisler Capital UK Ltd. bought a new position in shares of Eucrates Biomedical Acquisition during the fourth quarter worth approximately $2,269,000. Finally, Saba Capital Management L.P. increased its stake in shares of Eucrates Biomedical Acquisition by 379.6% during the first quarter. Saba Capital Management L.P. now owns 270,751 shares of the company’s stock worth $2,670,000 after purchasing an additional 214,300 shares during the period. Institutional investors own 54.48% of the company’s stock.

NASDAQ:EUCR remained flat at $$9.88 on Tuesday. The company’s stock had a trading volume of 53 shares, compared to its average volume of 12,059. The firm has a 50 day moving average of $9.86 and a two-hundred day moving average of $9.83. Eucrates Biomedical Acquisition has a 12-month low of $9.65 and a 12-month high of $10.77.

Eucrates Biomedical Acquisition Company Profile (Get Rating)

Eucrates Biomedical Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Recommended Stories

Receive News & Ratings for Eucrates Biomedical Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eucrates Biomedical Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.